UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.073

Sortiert nach

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update

Journal of clinical oncology, 2020-04, Vol.38 (12), p.1346-1366

2020

Volltextzugriff (PDF)

Global post-mortem tissue donation programmes to accelerate cancer research

Nature reviews. Cancer, 2024-05, Vol.24 (5), p.289

2024

Volltextzugriff (PDF)

Molecular Characterization of Basal‐Like and Non‐Basal‐Like Triple‐Negative Breast Cancer

The oncologist (Dayton, Ohio), 2013-02, Vol.18 (2), p.123-133

2013

Volltextzugriff (PDF)

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

Journal of clinical oncology, 2021-05, Vol.39 (13), p.1485-1505

2021

Volltextzugriff (PDF)

Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update

Archives of pathology & laboratory medicine (1976), 2020-05, Vol.144 (5), p.545-563

2020

Volltextzugriff (PDF)

Triple negative breast cancer: Pitfalls and progress

NPJ breast cancer, 2022-08, Vol.8 (1), p.95-95, Article 95

2022

Volltextzugriff (PDF)

Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer

Clinical breast cancer, 2009-06, Vol.9 (Suppl 2), p.S73-S81

2009

Volltextzugriff (PDF)

Triple-negative breast cancer: disease entity or title of convenience?

Nature reviews. Clinical oncology, 2010-12, Vol.7 (12), p.683-692

2010

Volltextzugriff (PDF)

Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid Recommendation Update

Journal of clinical oncology, 2022-09, Vol.40 (26), p.3088-3090

2022

Volltextzugriff (PDF)

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Journal of clinical oncology, 2020-12, Vol.38 (36), p.4274-4282

2020

Volltextzugriff (PDF)

Understanding and treating triple-negative breast cancer

Oncology (Williston Park, N.Y.), 2008-10, Vol.22 (11), p.1233-9; discussion 1239-40

2008

Volltextzugriff (PDF)

Directed Therapy of Subtypes of Triple‐Negative Breast Cancer

The oncologist (Dayton, Ohio), 2011-01, Vol.16 (S1), p.71-78

Carey, Lisa A.

2011

Volltextzugriff (PDF)

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)

Journal of clinical oncology, 2015-01, Vol.33 (1), p.13-21

2015

Volltextzugriff (PDF)

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures

BMC genomics, 2011-01, Vol.4 (1), p.3-3, Article 3

2011

Volltextzugriff (PDF)

Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update

Journal of clinical oncology, 2023-02, Vol.41 (6), p.1318-1320

2023

Volltextzugriff (PDF)

Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study

Breast cancer research : BCR, 2016-08, Vol.18 (1), p.79-79, Article 79

2016

Volltextzugriff (PDF)

CYP2D6 and tamoxifen: DNA matters in breast cancer

Nature reviews. Cancer, 2009-08, Vol.9 (8), p.576-586

2009

Volltextzugriff (PDF)

Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer

The Journal of clinical investigation, 2018-04, Vol.128 (4), p.1371-1383

2018

Volltextzugriff (PDF)

Targeting brain metastases in breast cancer

Cancer treatment reviews, 2022-02, Vol.103, p.102324-102324, Article 102324

2022

Volltextzugriff (PDF)

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

Journal of clinical oncology, 2016-02, Vol.34 (6), p.542-549

2016

Volltextzugriff (PDF)

Asparagine bioavailability governs metastasis in a model of breast cancer

Nature (London), 2018-02, Vol.554 (7692), p.378-381

2018

Volltextzugriff (PDF)

The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer

Annals of surgical oncology, 2015-03, Vol.22 (3), p.874-882

2015

Volltextzugriff (PDF)

Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases

PLoS medicine, 2016-12, Vol.13 (12), p.e1002174-e1002174

2016

Volltextzugriff (PDF)

The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

Clinical cancer research, 2007-04, Vol.13 (8), p.2329-2334

2007

Volltextzugriff (PDF)

What is triple-negative breast cancer?

European journal of cancer (1990), 2008-12, Vol.44 (18), p.2799-2805

2008

Volltextzugriff (PDF)

1 – 25 von 1.073

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(990)
Mit Volltextzugriff
(938)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.072)
Japanisch
(108)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update

Global post-mortem tissue donation programmes to accelerate cancer research

Molecular Characterization of Basal‐Like and Non‐Basal‐Like Triple‐Negative Breast Cancer

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update

Triple negative breast cancer: Pitfalls and progress

Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer

Triple-negative breast cancer: disease entity or title of convenience?

Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Rapid Recommendation Update

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Understanding and treating triple-negative breast cancer

Directed Therapy of Subtypes of Triple‐Negative Breast Cancer

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures

Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update

Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study

CYP2D6 and tamoxifen: DNA matters in breast cancer

Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer

Targeting brain metastases in breast cancer

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

Asparagine bioavailability governs metastasis in a model of breast cancer

The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer

Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases

The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

What is triple-negative breast cancer?

Suchergebnisse filtern